Colloquium (Mark C. Preul, MD)

September 17, 2014

3:00PM - 4:00PM

035 Psychology building

Add to Calendar 2014-09-17 15:00:00 2014-09-17 16:00:00 Colloquium (Mark C. Preul, MD) The Center for Cognitive and Behavioral Brain ImagingandThe Center for Cognitive and Brain SciencespresentsMark C. Preul, MDNewsome Family Endowed Chair of Neurosurgery ResearchDirector, Neurosurgery Research LaboratoryProfessor of Neuroscience and NeurosurgeryBarrow Neurological InstituteMeningiomas assessed with ex vivo NMR and in vivo 3D 1H-magnetic resonance spectroscopy:Determining biochemical markers of clinically aggressive behavior and providing a resection advantageAbstract:Explorations of human cerebral tumors using magnetic resonance spectroscopy have yielded special insight into their in vivo metabolic processes and pointed to means that could prove helpful in treatment. Much of our work has concentrated on malignant human cerebral tumors, yet meningiomas that make up nearly one third of intracranial tumors have received comparatively less attention. I will track the progress made in using ex vivo nuclear magnetic resonance spectroscopy (NMR) of resected meningioma tissue by the BNI meningioma study collaboration showing that meningiomas are made up of biochemically heterogeneous regions, and that the quantities of various biochemical markers are correlated to specific genetic markers of aggression. The background work allowed us to test the hypothesis that in vivo,multivoxel, three-dimensional proton magnetic resonance spectroscopic imaging (3D 1H-MRSI) can be used to identify regional biochemical alterations unique to clinically aggressive meningiomas and suggest that 3D 1H-MRSI can—non-invasively—detect more aggressive regions within individual meningiomas. Non-invasive detection of various intratumoral biochemical markers using 3D 1H-MRSI can distinguish more aggressive or recurrent from newly-diagnosed meningiomas. There is significant regional heterogeneity in the concentrations of these markers within individual tumors. Furthermore, 3D 1H-MRSI can exploit these regional differences to separate more aggressive from less aggressive areas within a given meningioma, and can be incorporated into a standard neurosurgical image-guidance platform to be used intraoperatively. Such knowledge may be useful to the neurosurgeon faced with the task of meningioma resection, and in planning adjuvant therapy for residual meningioma tissue following subtotal removal. 035 Psychology building OSU ASC Drupal 8 ascwebservices@osu.edu America/New_York public

Add to Calendar 2014-09-17 15:00:00 2014-09-17 16:00:00 Colloquium (Mark C. Preul, MD) The Center for Cognitive and Behavioral Brain ImagingandThe Center for Cognitive and Brain SciencespresentsMark C. Preul, MDNewsome Family Endowed Chair of Neurosurgery ResearchDirector, Neurosurgery Research LaboratoryProfessor of Neuroscience and NeurosurgeryBarrow Neurological InstituteMeningiomas assessed with ex vivo NMR and in vivo 3D 1H-magnetic resonance spectroscopy:Determining biochemical markers of clinically aggressive behavior and providing a resection advantageAbstract:Explorations of human cerebral tumors using magnetic resonance spectroscopy have yielded special insight into their in vivo metabolic processes and pointed to means that could prove helpful in treatment. Much of our work has concentrated on malignant human cerebral tumors, yet meningiomas that make up nearly one third of intracranial tumors have received comparatively less attention. I will track the progress made in using ex vivo nuclear magnetic resonance spectroscopy (NMR) of resected meningioma tissue by the BNI meningioma study collaboration showing that meningiomas are made up of biochemically heterogeneous regions, and that the quantities of various biochemical markers are correlated to specific genetic markers of aggression.  The background work allowed us to test the hypothesis that in vivo,multivoxel, three-dimensional proton magnetic resonance spectroscopic imaging (3D 1H-MRSI) can be used to identify regional biochemical alterations unique to clinically aggressive meningiomas and suggest that 3D 1H-MRSI can—non-invasively—detect more aggressive regions within individual meningiomas.  Non-invasive detection of various intratumoral biochemical markers using 3D 1H-MRSI can distinguish more aggressive or recurrent from newly-diagnosed meningiomas.  There is significant regional heterogeneity in the concentrations of these markers within individual tumors.  Furthermore, 3D 1H-MRSI can exploit these regional differences to separate more aggressive from less aggressive areas within a given meningioma, and can be incorporated into a standard neurosurgical image-guidance platform to be used intraoperatively. Such knowledge may be useful to the neurosurgeon faced with the task of meningioma resection, and in planning adjuvant therapy for residual meningioma tissue following subtotal removal. 035 Psychology building Center for Cognitive and Brain Sciences ccbs@osu.edu America/New_York public

The Center for Cognitive and Behavioral Brain Imaging

and

The Center for Cognitive and Brain Sciences

presents

Mark C. Preul, MD

Newsome Family Endowed Chair of Neurosurgery Research

Director, Neurosurgery Research Laboratory

Professor of Neuroscience and Neurosurgery

Barrow Neurological Institute

Meningiomas assessed with ex vivo NMR and in vivo 3D ¹H-magnetic resonance spectroscopy:

Determining biochemical markers of clinically aggressive behavior and providing a resection advantage

Abstract:

Explorations of human cerebral tumors using magnetic resonance spectroscopy have yielded special insight into their in vivo metabolic processes and pointed to means that could prove helpful in treatment. Much of our work has concentrated on malignant human cerebral tumors, yet meningiomas that make up nearly one third of intracranial tumors have received comparatively less attention. I will track the progress made in using ex vivo nuclear magnetic resonance spectroscopy (NMR) of resected meningioma tissue by the BNI meningioma study collaboration showing that meningiomas are made up of biochemically heterogeneous regions, and that the quantities of various biochemical markers are correlated to specific genetic markers of aggression. The background work allowed us to test the hypothesis that in vivo,multivoxel, three-dimensional proton magnetic resonance spectroscopic imaging (3D ¹H-MRSI) can be used to identify regional biochemical alterations unique to clinically aggressive meningiomas and suggest that 3D ¹H-MRSI can—non-invasively—detect more aggressive regions within individual meningiomas. Non-invasive detection of various intratumoral biochemical markers using 3D 1H-MRSI can distinguish more aggressive or recurrent from newly-diagnosed meningiomas. There is significant regional heterogeneity in the concentrations of these markers within individual tumors. Furthermore, 3D 1H-MRSI can exploit these regional differences to separate more aggressive from less aggressive areas within a given meningioma, and can be incorporated into a standard neurosurgical image-guidance platform to be used intraoperatively. Such knowledge may be useful to the neurosurgeon faced with the task of meningioma resection, and in planning adjuvant therapy for residual meningioma tissue following subtotal removal.